HFA
AZN icon

Hoover Financial Advisors’s AstraZeneca AZN Stock Holding History

Hoover Financial Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$35K Hold
294
– – 0.01% 330
2021
Q1 		$32K Hold
294
– – 0.01% 305
2020
Q4 		$30K Buy
+294
New +$31.1K 0.01% 281

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hoover Financial Advisors's AZN Position: Q2 2021 in Review

Hoover Financial Advisors held its AstraZeneca (AZN) position steady in Q2 2021 at 294 shares worth $35K. The position accounts for 0.01% of the portfolio, ranked #330.

Hoover Financial Advisors first reported a position in AZN in Q4 2020 and has held it in 3 quarters since. 769 funds tracked by Wall St. Rank hold AZN as of Q2 2021.

  • Hoover Financial Advisors held 294 shares of AstraZeneca worth $35K as of Q2 2021.
  • Hoover Financial Advisors left its AstraZeneca share count unchanged in Q2 2021.
  • AstraZeneca made up 0.01% of Hoover Financial Advisors's portfolio in Q2 2021, its #330 holding.
  • Hoover Financial Advisors first reported a position in AstraZeneca in Q4 2020 and has held it in 3 quarters since.
  • 769 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.